How tesamorelin's mechanism works

The proposed mechanism in outline

Tesamorelin is a modified copy of human growth hormone-releasing hormone (GHRH). The proposed mechanism is the one GHRH itself uses. The peptide binds the GHRH receptor on pituitary somatotroph cells, the receptor signals through cyclic AMP, and the cell makes and releases growth hormone (GH), which in turn raises insulin-like growth factor-1 (IGF-I). A chemical group added at the front end of the peptide slows its breakdown.

How well each step is established varies. The receptor biology rests on work with native GHRH in animal and cell systems. The GH and IGF-I response to tesamorelin has been measured in people. Everything further downstream is association, not a demonstrated pathway.

This page is only about how the compound is proposed to work. What it is and how it is classified is on the tesamorelin identity page. It is not a treatment guide, a recommendation or a human-use protocol.

Primary target: the GHRH receptor

Reviews of native GHRH describe a seven-transmembrane receptor coupled to a Gs protein on pituitary somatotrophs. Binding leads to release of GH from secretory granules and to a rise in intracellular cyclic AMP, then to activation of the transcription factor CREB and of Pit-1, which the GH gene needs (Mayo and colleagues, 1995). The receptor belongs to family B-III of the G protein-coupled receptor superfamily and is expressed mainly in the pituitary. It signals predominantly through cyclic AMP, with activation of the MAP kinase pathway also reported (Mayo and colleagues, 2000). Somatostatin is thought to oppose the same pathway by suppressing cyclic AMP.

These are studies of native GHRH. None of the papers cited here measures tesamorelin binding to the receptor directly. That it acts at this receptor is inferred from its structure as a 44-residue GHRH analogue and from the GH release it produces.

Model systems the targets were identified in

Demonstrated versus inferred

The liver work is paired biopsies from a randomised trial in people with HIV-associated fatty liver disease. Fourman and colleagues (2020) reported higher expression of oxidative-phosphorylation gene sets and lower expression of inflammation and cell-division gene sets. A companion analysis (Fourman and colleagues, 2021) found lower plasma VEGFA, TGFB1 and CSF1 than with placebo. Makimura and colleagues (2013) found that, in 39 obese adults with reduced GH secretion, the rise in IGF-I correlated with phosphocreatine recovery after exercise, which the authors read as suggestive of mitochondrial function. These are associations in specific patient groups. They are not a demonstrated route from receptor to outcome.

What the stabilising modification changes

Native GHRH is broken down quickly. Bovine growth hormone-releasing factor is a substrate for dipeptidyl peptidase IV, which removes its first two residues, Tyr and Ala (Martin and colleagues, 1993). That result is from pig kidney enzyme acting on bovine analogues, not from human tissue, but it explains where tesamorelin was modified.

Tesamorelin carries a trans-3-hexenoyl group on Tyr1 of the 44-residue human sequence. Its developers reported that the modification made it resistant to dipeptidyl peptidase IV, slowed its breakdown in rat, dog and human plasma, and prolonged its time in circulation in animals (Ferdinandi and colleagues, 2007). The same paper puts the apparent elimination half-life in dogs at 21 to 45 minutes. Stabilised therefore means a half-life of tens of minutes in that species, not hours or days. It does not mean unmetabolised either: an in vitro metabolism study of four GHRH analogues, tesamorelin among them, identified 19 major metabolites (Memdouh and colleagues, 2021).

In dogs, the developer's repeat-exposure studies also reported adverse effects that the authors attributed to prolonged exposure to high GH and IGF-1. A longer-lasting GHRH analogue changes the shape of the signal as well as its size.

How this differs from adjacent compounds

The contrast is in receptor and molecular design, not in a product comparison.

Tesamorelin, sermorelin and CJC-1295 are grouped together in the analytical literature as GHRH synthetic analogues (Memdouh and colleagues, 2021). Ipamorelin is mechanistically separate. It acts at a different receptor and is not a stronger or weaker version of a GHRH analogue. The three GHRH-class compounds are compared on ipamorelin, CJC-1295 and sermorelin.

Open questions

• Direct receptor data. Tesamorelin binding and signalling at the GHRH receptor are not measured in the papers cited here.
• Cause or consequence. Whether the liver and plasma-protein changes are direct effects or follow from the rise in IGF-I is not resolved.
• Population. Most of the human mechanistic work is in people with HIV-associated lipodystrophy, with fatty liver, or in obese adults with reduced GH. It does not describe other groups.
• Independence. The animal and stability data come from the developer. Most of the human mechanistic papers come from one academic group in Boston, and S K Grinspoon is an author on each of the five cited here.
• Reagent versus studied material. Published work describes the licensed product and the developer's material. Whether a given laboratory batch matches it is a question of identity and purity, which is what the COA publication status addresses.

EPS documentation

Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.